Tegavivint (** Tegafivint (investigational name); no approved commercial brand names as it remains in clinical development **)

Other Medications

EU Experimental ES Not available 2 Clinical Trials

Description

Tegavivint is an investigational medication currently being studied in clinical trials. It is being evaluated for its potential use in treating certain types of cancer, including some solid tumors in children and adolescents. In colorectal cancer, trials are exploring its use in patients whose tumors have specific genetic changes (mutations), such as APC, BRAF, EGFR, FBXW7, MET, or MSI-H status. The trials are in early phases (Phase 1), meaning researchers are primarily focused on determining the safest dose and looking for early signs of effectiveness. Tegavivint is given as an intravenous infusion.

Mechanism of Action

Tegavivint is being investigated for its potential to target the WNT/beta-catenin pathway, which plays a role in the growth of some cancers. The specific molecular target and detailed mechanism of action are still being characterized in clinical trials. Exploratory objectives of the trials include testing whether activity of the WNT/beta-catenin pathway correlates with response to the drug and characterizing pharmacodynamic changes related to target engagement.

Side Effects

As tegavivint is an investigational drug in early-phase trials The full range of potential side effects is still being evaluated. The primary focus of the current trials is to determine the maximum tolerated dose and assess safety. Information on specific side effects will become clearer as trials progress. Patients enrolled in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07463599 Phase 1
Recruiting
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
United States
NCT04851119 Phase 1
Recruiting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
United States

Quick Info

Brand Name** Tegafivint (investigational name); no approved commercial brand names as it remains in clinical development **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.